Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Quantumscape Corp (QS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Quantumscape Corp — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Quantumscape Corp trades at $6.52 (market cap $4.05B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 9.8× Quantumscape Corp's market cap. Which is the better fit depends on your goals.
| ALNY | QS | |
|---|---|---|
Market Cap | $39.89B | $4.05B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $18.44 |
52-Week Low | $278.09 | $5.96 |
Enterprise Value | $38.15B | $3.21B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
QuantumScape (QS) trades at $6.58, down 4.78% today, with a bearish technical outlook and negative profitability metrics. The company reported a net loss of $435.05 million in 2025, though cash flow improved to a net positive $85.27 million. Recent news highlights a joint research agreement with Honda, providing optimism for solid-state battery development. Analyst consensus is cautious, with 73% hold ratings and no buy recommendations.
The outlook remains speculative due to high cash burn and unproven commercialization. Risks include execution delays and EV market volatility. Upside depends on successful battery deployment, but near-term financial pressure and bearish sentiment suggest cautious investor positioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Quantumscape Corp
QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles. It developed anode-less cell design, which delivers high energy density while lowering material costs and simplifying manufacturing.
Read more on QS →
